Is Bristol-Myers Squibb (BMY) Stock Cheap, Or Are Risks Priced In?

Bristol-Myers Squibb has had a strong run over the past year, and recent trial updates plus fresh AI partnerships have kept the story moving. With the stock now reflecting a mix of oncology progress and new data risks, investors are asking whether the current price lines up with the cash flows the business can generate and sustain.

• The share price has gained 40.6% over the past 12 months, which puts more weight on the question of whether the current valuation is fully backed by the company’s underlying cash generation.
• New oncology and neurology programs, including CAR T and antibody drug conjugate work alongside AI data collaborations, can influence expectations for future cash inflows and the timing of development spending.
• Prefer to judge Bristol-Myers Squibb on earnings? See what Bristol-Myers Squibb's 13.5x P/E says about the price.

The issue now is whether Bristol-Myers Squibb's current share price is appropriately explained by the cash flows implied in its intrinsic value estimate under the Discounted Cash Flow (DCF) approach.

To stress test whether Bristol-Myers Squibb's AI driven oncology story and cash flow profile feel compelling, it helps to compare it with other 36 healthcare AI stocks.

Is Bristol-Myers Squibb a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) approach here focuses on the cash Bristol-Myers Squibb can return to shareholders over time. Latest twelve month free cash flow sits around $11.5b, which is a sizeable base for a mature pharmaceutical group with an expanding oncology and neurology pipeline.

Projections in this 2 Stage Free Cash Flow to Equity model assume roughly stable to slightly declining free cash flows over the next decade rather than a sharp ramp up. They point to an estimated intrinsic value that the analysis describes as substantially above the current share price of $61.39. The interim Phase 1 CAR T update, including the reported patient death, helps explain why the market may be more cautious even as the cash flow profile appears supported by large existing franchises and AI fuelled research partnerships. Find out what Bristol-Myers Squibb could be worth using our Discounted Cash Flow (DCF) estimate.

The Bristol-Myers Squibb Narrative: What Would Justify Today's Price?

Narratives pick up where the DCF puzzle leaves off by explaining which assumptions about Bristol-Myers Squibb's future growth, margins and earnings would need to hold for the current valuation to appear either stretched or too low, and they sit on Simply Wall St's Community page. Each scenario links a fair value estimate to a particular mix of potential catalysts and threats in Bristol-Myers Squibb's story so you can track which version seems to be unfolding over time.

Community views on Bristol-Myers Squibb are now split between those who see meaningful upside from the next wave of products and those who think the price already reflects the story.

Bull case: 23% undervalued

"CELMoD readouts like the positive Phase 3 EXCALIBER RRMM result for iberdomide, combined with prelaunch spending that is now embedded in operating expenses..."

Discover why this Narrative puts Bristol-Myers Squibb at 23% undervalued.

Bear case: 115% overvalued

"What holds me back is not quality but price: at current levels the stock trades above fair value and above my entry filters..."

Explore why this Narrative puts Bristol-Myers Squibb at 115% overvalued.

The unanswered piece of Bristol-Myers Squibb's story

One crucial layer still unchecked is who is actually steering Bristol-Myers Squibb and how their pay packages line up with the risks, timelines and trade offs built into this valuation story. See who runs Bristol-Myers Squibb and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com